Fig. 3
CD134 and/or SU vaccinated cats were not protected against FIV challenge. a All Protocol I study animals demonstrated positive viremia by week 2 post FIV infection, and FIV RNA levels were significantly elevated at week 2 in SU vaccinated (p < 0.001) and CD134+SU vaccinated (p < 0.05) cats; suggesting a transient enhancement of FIV infection. b Proviral DNA was detected in PBMCs of all Protocol I study animals by week 2 post FIV infection, but did not differ between vaccine groups over time. c All Protocol II study animals demonstrated FIV RNA in plasma by week 2 post infection. FIV RNA levels decreased significantly over time in all groups (time p < 0.001); however, no significant differences were observed between vaccine groups over time during this phase of the study. d Proviral DNA was detected in PBMCs of all Protocol II study animals at week 1 post FIV infection, and were significantly elevated above baseline (pre-FIV challenge, week 20) in all study groups by week 2 post FIV infection (RM-ANOVA). Proviral DNA levels did not differ over time or between vaccine groups during Protocol II
